Abstract
It is unusual for patients with inflammatory bowel disease (IBD) to present with almost specific or pathognomonic clinical symptoms and signs. This implies that diagnosing Crohn’s disease (CD) or ulcerative colitis (UC) is substantially dependent on the combination of a wide range of clinical, radiological, endoscopic, and histological findings that should be correctly interpreted by physicians in the appropriate setting. One additional important point is linked to recent advances in the field that have led to the widespread use of biological therapies in the management of patients with IBD, either CD or UC. This suggests that we urgently need reliable tools to stratify patients with different disease subtypes in terms of the risk of complications and a poor outcome as well as the probability to clinically respond to one treatment strategy, including biological therapies, rather than to others. Reliable tools are also required to appropriately follow-up patients during the course of their disease, especially methods that allow inflammatory activity and treatment effects to be monitored.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Pepys MB, Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Invest 111:1805–1812
Vermeire S, Van Assche G, Rutgeerts P (2004) C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 10:661–665
Vermeire S, Van Assche G, Rutgeerts P (2005) The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2:580–586
Gross V, Andus T, Caesar I et al (1992) Evidence for continuous stimulation of interleukin-6 production in Crohn’s disease. Gastroenterology 102:514–519
Tromm A, Tromm CD, Huppe D et al (1992) Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn’s disease. Scand J Gastroenterol 27:774–778
Nielsen OH, Vainer B, Madsen SM et al (2000) Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 95:359–367
Solem CA, Loftus EV Jr, Tremaine WJ et al (2005) Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 11:707–712
Florin TH, Paterson EW, Fowler EV et al (2006) Clinically active Crohn’s disease in the presence of a low C-reactive protein. Scand J Gastroenterol 41:306–311
Cellier C, Sahmoud T, Froguel E et al (1994) Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn’s disease. A prospective multicentre study of 121cases. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 35:231–235
Lemann M, Mary JY, Colombel JF et al (2005) A randomized, double-blind, controlled with-drawl trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology 128:1812–1818
Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F (1988) The clinical significance of serum C reactive protein levels in Crohn’s disease. Results of a prospective longitudinal study. J Clin Gastroenterol 10:401–405
Travis SP, Farrant JM, Ricketts C et al (1996) Predicting outcome in severe ulcerative colitis. Gut 38:905–910
Louis E, Vermeire S, Rutgeerts P et al (2002) A positive response to infliximab in Crohn’s disease: association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism. Scand J Gastroenterol 37:818–824
Beaven SW, Abreu MT (2004) Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol 20:318–327
Tibble J, Teahon K, Thjodleifsson B et al (2000) A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 47:506–513
Poullis A, Foster R, Northfield TC, Mendall MA (2002) Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther 16:675–681
Aadland E, Fagerhol MK (2002) Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 14:823–825
Summerton CB, Longlands MG, Wiener K, Shreeve DR (2002) Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 14:841–845
Costa F, Mumolo MG, Bellini M et al (2003) Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 35:642–647
Thjodleifsson B, Sigthorsson G, Cariglia N et al (2003) Subclinical intestinal inflammation: an inherited abnormality in Crohn’s disease relatives? Gastroenterology 124:1728–1737
Bunn SK, Bisset WM, Main MJ et al (2001) Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 33:14–22
Roseth AG, Aadland E, Jahnsen J, Raknerud N (1997) Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 58:176–180
Costa F, Mumolo MG, Ceccarelli L et al (2005) Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut 54:364–368
Tibble JA, Sigthorsson G, Bridger S et al (2000) Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119:15–22
Roseth AG, Aadland E, Grzyb K (2004) Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 39:1017–1020
Vaishnavi C, Kochhar R, Bhasin D et al (2003) Simultaneous assays for Clostridium difficile and faecal lactoferrin in ulcerative colitis. Trop Gastroenterol 24:13–16
Kane SV, Sandborn WJ, Rufo PA et al (2003) Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 98:1309–1314
Silberer H, Kuppers B, Mickisch O et al (2005) Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab 51:117–126
Buderus S, Boone J, Lyerly D, Lentze MJ (2004) Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig Dis Sci 49:1036–1039
Ferrante M, Henckaerts L, Joossens M et al (2007) New serological markers in in inflammatory bowel disease are associated with complicated disease behaviour. Gut 56:1394–1403
Schoepfer AM, Schaffer T, Mueller S et al (2009) Phenotypic associations of Crohn’s disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a swiss cohort. Inflamm Bowel Dis (in press)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Italia
About this chapter
Cite this chapter
Famularo, G., Minisola, G. (2010). Laboratory Tests. In: Tersigni, R., Prantera, C. (eds) Crohn’s Disease. Updates in Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-1472-5_7
Download citation
DOI: https://doi.org/10.1007/978-88-470-1472-5_7
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-1471-8
Online ISBN: 978-88-470-1472-5
eBook Packages: MedicineMedicine (R0)